Clinical significance of dornase alfa (Pulmozyme) in complex therapy of early age children suffering cystic fybrosis


Cite item

Full Text

Abstract

We considered the pathogenic mechanisms, clinical presentation and principles of treatment of cystic fibrosis. Data for retrospective study of clinical efficacy and safety of long-term administration of recombinant human DNase (dornaza alpha; Pulmozim) in infants with cystic fibrosis are presented. The results confirm the Pulmozim safety and efficacy in this group of patients. The frequency of respiratory episodes is decreased by 42.37 due to Pulmozim administration. It is emphasized that early Pulmozim administration helps in the prevention of respiratory episodes, reduction of inflammatory activity in the lungs, improvement of nutritional status, and in the future - improvement of quality and extended life-span in patients with cystic fibrosis.

References

  1. Капранов Н.И., Каширская Н.Ю., Толстова В.Д. Муковисцидоз. Ранняя диагностика и лечение. М., 2008. С. 104.
  2. Koch C, Hoiby NS. Pathogenesis of cystic fibrosis. Lancet 1993;341:1065-69.
  3. Kirchner KK, Wagener JS, Khan TZ, et al. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996;154(5):1426-29.
  4. Massion PP, Inou H, Richman-Eisenstat J, et al. Novel Pseudomonas product stimulates interlrukin-8 production in airway epithelial cells in vitro. J Clin Invest 1994;93:26-32.
  5. Ruef C, Jefferson DM, Schlegel-Hauter SE, et al. Regulation of cytokine secretion by cystic fibrosis airway epithelial cells. Eur Respir J 1993;6:1429-36.
  6. Shmarina GV, Pukhalsky AL, Kokarovtseva SN, et al. Tumor necrosis factor-alfa/interleukin-10 balance in normal and cystic fibrosis children. Mediators of Inflammation 2001;10:191-97.
  7. Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site the pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84:1303-13.
  8. Regnis JA, Robinson M, Baileu DL. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71.
  9. Ratjen F, Paul K, van Koningsbruggen S, et al. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. Pediatr Pulmonol 2005;39(1):1-4.
  10. Frederiksen B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 2006;95(9):1070-74.
  11. Капранов Н.И., Воронкова А.Ю., Каширская Н.Ю. и др. Комплексное лечение муковисцидоза у детей раннего возраста: клиническое значение дорназы-альфа // Клиницист. 2007. № 2. С. 60-65.
  12. Богданова Т.А., Каширская Н.Ю., Толстова В.Д. и др. Клиническая эффективность и безопасность пульмозима (дорназа альфа) у детей раннего возраста, больных муковисцидозом // Российский вестник перинатологии и педиатрии. 2008. Т. 53. № 4. С. 35-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies